Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Publication year range
2.
Cell Death Differ ; 20(1): 21-30, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22722335

ABSTRACT

Ubiquitination has long been recognised as a key determinator of protein fate by tagging proteins for proteasomal degradation. Most recently, the ability of conjugated ubiquitin chains to confer selectivity to autophagy was demonstrated. Although autophagy was first believed to be a bulk, non-selective 'self-eating' degradative process, the molecular mechanisms of selectivity are now starting to emerge. With the discovery of autophagy receptors - which bind both ubiquitinated substrates and autophagy specific light chain 3 (LC3) modifier on the inner sheath of autophagosomes - a new pathway of selective autophagy is being unravelled. In this review, we focus on the special role of ubiquitin signals and selective autophagy receptors in sorting a variety of autophagic cargos.


Subject(s)
Autophagy/physiology , Ubiquitin/metabolism , Ubiquitination/physiology , Humans , Signal Transduction
3.
J Immunother ; 24(4): 384-8, 2001.
Article in English | MEDLINE | ID: mdl-11565840

ABSTRACT

Transforming growth factor (TGF)-beta3 has been hypothesized to prevent or alleviate oral mucositis (OM) in cancer patients receiving high-dose chemotherapy (CT). Two double-blind, placebo-controlled, multicenter, phase II studies of TGF-beta3 were initiated in the United States, Europe, and Argentina in patients with lymphomas or solid tumors who were receiving highly stomatotoxic CT regimens. Patients were to apply 10-mL mouthwash applications of TGF-beta3 (25 microg/mL) or placebo four times daily (or twice daily) 1 day before and all days during CT. The patients were subsequently evaluated for OM incidence, severity, and duration using National Institute of Cancer Common Toxicity Criteria (NCI-CTC) criteria and an objective scoring system (1). After the start of the trials, negative results from new preclinical studies suggesting suboptimal formulation and/or dosing led to an interim analysis of the ongoing clinical trials. One hundred fifty-two patients from the combined studies were included in the interim analysis, with 116 patients on the TGF-beta3 four times daily and placebo arms. Most (72%) patients had breast cancer, 22% had lymphomas, and 6% had other solid tumors. Although 98% (149 of 152) of patients experienced adverse events, only 14% (22 of 152) experienced events that were judged as possibly or probably related to the study drug (primarily gastrointestinal symptoms). No clinically relevant differences were seen between the treatment and placebo arms regarding safety, nor was there evidence for systemic absorption of TGF-beta3. Finally, there was no advantage of TGF-beta3 treatment regarding the incidence (TGF-beta3 four times daily versus placebo [46% versus 47%]), onset, or duration of NCI-CTC grade 3 or 4 OM. For this dose, formulation, regimen. and patient population, TGF-beta3 was not effective in the prevention or alleviation of CT-induced OM.


Subject(s)
Antineoplastic Agents/adverse effects , Mouth Mucosa/drug effects , Neoplasms/drug therapy , Transforming Growth Factor beta/therapeutic use , Adult , Aged , Double-Blind Method , Female , Humans , Inflammation/chemically induced , Inflammation/drug therapy , Lymphoma/drug therapy , Male , Middle Aged , Mouthwashes , Placebos , Pregnancy , Transforming Growth Factor beta/administration & dosage
4.
Cancer Res ; 61(5): 2105-11, 2001 Mar 01.
Article in English | MEDLINE | ID: mdl-11280773

ABSTRACT

The tumor suppressor PTEN is one of the most commonly inactivated genes in human cancer. Glioblastoma multiforme cells harboring mutant PTEN have abnormally high levels of 3' phosphoinositides and elevated protein kinase B activity. Expression of wild-type PTEN in glioma cells, containing endogenous mutant PTEN, reduces 3' phosphoinositides levels, inhibits PKB activity, and induces G1 cell cycle arrest. We investigated the mechanism of the PTEN-induced growth arrest in glioma cell lines. Expression of PTEN is associated with increased expression of p27Kip1, decreased expression of cyclins A and D3, inhibition of cdk2 activity, and dephosphorylation of pRb. Inactivation of p53, by the human papilloma virus E6 oncoprotein, does not prevent PTEN-induced G1 arrest, implying that p53 is not required for G1 arrest. In contrast, p27Kip1 antisense oligonucleotides abrogated the growth arrest induced by PTEN. Furthermore, blocking p27Kip1 expression prevented the PTEN-induced reduction of cyclin-dependent kinase 2 activity, indicating that p27Kip1 functions upstream of cyclin-dependent kinase 2 in the PTEN regulatory cascade. These results implicate p27Kip1 as a critical mediator of PTEN-induced G1 arrest.


Subject(s)
CDC2-CDC28 Kinases , G1 Phase/physiology , Microtubule-Associated Proteins/physiology , Phosphoric Monoester Hydrolases/physiology , Tumor Suppressor Proteins , Cell Cycle Proteins/biosynthesis , Cell Cycle Proteins/physiology , Cell Division/physiology , Chromones/pharmacology , Cyclin-Dependent Kinase 2 , Cyclin-Dependent Kinase Inhibitor p27 , Cyclin-Dependent Kinases/physiology , Enzyme Inhibitors/pharmacology , Glioma/pathology , Humans , Microtubule-Associated Proteins/biosynthesis , Morpholines/pharmacology , PTEN Phosphohydrolase , Phosphoinositide-3 Kinase Inhibitors , Phosphoric Monoester Hydrolases/genetics , Protein Serine-Threonine Kinases/physiology , Signal Transduction/drug effects , Signal Transduction/physiology , Tumor Cells, Cultured , Tumor Suppressor Protein p53/physiology , Up-Regulation/physiology
5.
Nat Med ; 6(10): 1128-33, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11017144

ABSTRACT

The adenovirus mutant dl1520 (ONYX-015) does not express the E1B-55K protein that binds and inactivates p53. This virus replicates in tumor cells with mutant p53, but not in normal cells with functional p53. Although intra-tumoral injection of dl1520 shows promising responses in patients with solid tumors, previous in vitro studies have not established a close correlation between p53 status and dl1520 replication. Here we identify loss of p14ARF as a mechanism that allows dl1520 replication in tumor cells retaining wild-type p53. We demonstrate that the re-introduction of p14ARF into tumor cells with wild-type p53 suppresses replication of dl1520 in a p53-dependent manner. Our study supports the therapeutic use of dl1520 in tumors with lesions within the p53 pathway other than mutation of p53.


Subject(s)
Adenoviridae/genetics , Mutation , Nuclear Proteins , Proteins/genetics , Virus Replication , Gene Expression Regulation, Neoplastic , Humans , Proteins/metabolism , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-mdm2 , Tumor Cells, Cultured/virology , Tumor Suppressor Protein p14ARF , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism
7.
Wien Klin Wochenschr ; 112(23): 1014-5, 2000 Dec 07.
Article in English | MEDLINE | ID: mdl-11190710

ABSTRACT

Body temperature follows a circadian rhythm with a low around 6 a.m. and a peak about 12 hours later. The effect of fever on this endogenous oscillation is unknown. We obtained hourly measurements of the rectal temperature of 66 children with Plasmodium falciparum malaria. Even at febrile temperatures, the temperature followed a clear circadian rhythm. 33 patients (50%) had fever above 38 degrees C at 6 p.m. on the first day compared to only 9 (14%) at 6 a.m. the next morning. This considerable difference was also found on the second day of observation. Since in clinical practice antipyretics are often given above a certain fever threshold, the time of day should be taken into account when antipyretics are applied.


Subject(s)
Body Temperature Regulation/physiology , Circadian Rhythm/physiology , Fever/physiopathology , Malaria, Falciparum/physiopathology , Child , Child, Preschool , Female , Gabon , Humans , Malaria, Falciparum/diagnosis , Male , Reference Values
8.
Lancet ; 350(9079): 704-9, 1997 Sep 06.
Article in English | MEDLINE | ID: mdl-9291905

ABSTRACT

BACKGROUND: Routine antipyretic therapy in children with infectious diseases has long been the source of controversy. Each year, in addition to antimalarial medication, millions of children with Plasmodium falciparum malaria receive paracetamol to reduce fever. However, the usefulness of this practice has not been proven. METHODS: In a randomised trial in Lambaréné, Gabon, 50 children with P falciparum malaria were treated with intravenous quinine, and received either mechanical antipyresis alone, or in combination with paracetamol. Rectal body temperature and parasitaemia were recorded every 6 h for 4 days. Plasma concentrations and inducible concentrations of tumour necrosis factor (TNF) and interleukin-6 were measured every 24 h. In addition, production of oxygen radicals was measured in both groups. FINDINGS: The mean fever clearance time was 32 h for children treated with paracetamol and 43 h for those who received mechanical antipyresis alone; however, this 11 h difference was not significant (95% CI -2 to 24 h; p = 0.176). Parasite clearance time was significantly prolonged in patients who received paracetamol with a difference of 16 h (8-24 h; p = 0.004). Plasma concentrations of TNF and interleukin-6 were similar in both groups during the study. However, the induced concentrations of TNF, and the production of oxygen radicals, were significantly lower in children treated with paracetamol than those who received mechanical antipyresis alone. INTERPRETATION: These data suggest that paracetamol has no antipyretic benefits over mechanical antipyresis alone in P falciparum malaria. Moreover, paracetamol prolongs parasite clearance time, possibly by decreased production of TNF and oxygen radicals.


PIP: Although paracetamol is routinely used to control fever in African children with Plasmodium falciparum, the usefulness of this treatment has not been established. In a randomized clinical trial, 50 children 2-7 years of age from Lambarene, Gabon, with P. falciparum malaria were treated with intravenous quinine and received either mechanical antipyresis alone (electric fanning, tepid sponging, and cool blankets) or in combination with paracetamol. The mean fever clearance time was 32 hours for children treated with paracetamol and 43 hours for those who received antipyresis alone--a nonsignificant difference. Parasite clearance time was significantly prolonged (by an average of 16 hours) in children who received paracetamol. Although plasma concentrations of tumor necrosis factor and interleukin-6 were similar in both groups, induced concentrations of tumor necrosis factor and the production of oxygen radicals were significantly lower in paracetamol-treated children. Overall, these findings indicate that paracetamol confers no benefits over mechanical antipyresis alone and actually prolongs parasite clearance time. Further studies are required, however, before recommendations for ancillary treatment can be changed.


Subject(s)
Acetaminophen/therapeutic use , Analgesics, Non-Narcotic/therapeutic use , Fever/drug therapy , Malaria, Falciparum/parasitology , Plasmodium falciparum/drug effects , Acetaminophen/pharmacology , Analgesics, Non-Narcotic/pharmacology , Animals , Child , Child, Preschool , Female , Fever/etiology , Fever/therapy , Humans , Interleukin-6/blood , Malaria, Falciparum/complications , Malaria, Falciparum/drug therapy , Male , Reactive Oxygen Species/metabolism , Tumor Necrosis Factor-alpha/analysis , Tumor Necrosis Factor-alpha/drug effects
9.
Sante ; 7(4): 271-4, 1997.
Article in French | MEDLINE | ID: mdl-9410454

ABSTRACT

The roles of the various factors implicated in the pathogenesis of severe malaria are not well understood. Tumor necrosis factor (TNF), a cytokine produced mainly by macrophages, seems to play a crucial role in both the host's defence against the parasite and the development of severe complications. This review investigates the dual role of TNF in acute malaria, summarizing current knowledge of the beneficial and detrimental effects of this molecule. Recent work has suggested a possible explanation for this dualism, involving a complex interaction between TNF and its soluble receptors.


Subject(s)
Malaria/physiopathology , Tumor Necrosis Factor-alpha/physiology , Animals , Antimalarials/therapeutic use , Humans , Macrophages/physiology , Malaria/prevention & control , Receptors, Tumor Necrosis Factor/physiology , Tumor Necrosis Factor-alpha/adverse effects , Tumor Necrosis Factor-alpha/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...